REG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Half-Year Results

HUTCHMED (China)Announcement

Yesterday 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nRSC4598Pa&default-theme=true

RNS Number : 4598P  Hutchmed (China) Limited  03 July 2025

HUTCHMED to Announce 2025 Half-Year Financial Results

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, July 3, 2025: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM: HCM;
HKEX:13) will announce its interim results for the six months ended June 30,
2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) /
12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

 

HUTCHMED management will host two webcast presentations for analysts and
investors to discuss the interim results, followed by Q&A sessions. The
English webcast will be held on Thursday, August 7, 2025, at 8:00 am EDT (1:00
pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am
HKT / 1:30 am BST on Friday, August 8, 2025 (8:30 pm EDT on Thursday, August
7, 2025).

 

Both webcasts will be available live via the company website at
www.hutch-med.com/event/ (https://www.hutch-med.com/event/) . The presentation
will be available to download shortly before the webcast begins. A replay will
also be available on the website shortly after the event.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch-med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS

 

 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Alex Shaw                              +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUUUORVNUBRAR